Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns

Amneal Pharmaceuticals, Inc.

2025-Q2 EPS reported $0.11 revenue$1,419,928,000

Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.
Adjusted EBITDA $180M-$185M (+13% YoY); gross leverage 3.8x, net leverage 3.7x.
Director Emily Peterson Alva resigned July 16 after Amneal Group ownership dropped below majority of Class A common stock.
Brekiya autoinjector approved for migraine/cluster headache; CREXONT uptake strong; biosimilar to XOLAIR BLA expected Q4 2025.
Full year 2025 guidance expected to be met or exceeded based on year-to-date performance.

item 2.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.